Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.

The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.

The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.

The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide.

Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.